欢迎访问《中国癌症杂志》官方网站，今天是
图片表格检索 高级检索

中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (5): 321-327.doi: 10.19401/j.cnki.1007-3639.2020.05.001

• 论著 • 上一篇    下一篇

大型单中心医院登记的7 753例肺癌手术患者生存报告：基于第8版国际肺癌TNM分期标准

王泽洲 1 ，张　扬 2 ，莫　淼 1 ，袁　晶 1 ，周昌明 1 ，沈　洁 1 ，吴浩旋 2 ，李　航 2 ， 叶　挺 2 ，胡　鸿 2 ，陈海泉 2 ，郑　莹 1   

  1. 1. 复旦大学附属肿瘤医院肿瘤预防部，复旦大学上海医学院肿瘤学系，上海 200032 ；
    2. 复旦大学附属肿瘤医院胸外科，复旦大学上海医学院肿瘤学系，上海 200032
  • 出版日期:2020-05-30 发布日期:2020-06-05
  • 通信作者: 郑　莹 E-mail: zhengying@fudan.edu.cn

Survival report of 7 753 surgical lung cancer patients from a large single hospital-based cancer registry: results based on the 8th edition of the TNM classification of lung cancer

WANG Zezhou 1 , ZHANG Yang 2 , MO Miao 1 , YUAN Jing 1 , ZHOU Changming 1 , SHEN Jie 1 , WU Haoxuan 2 , LI Hang 2 , YE Ting 2 , HU Hong 2 , CHEN Haiquan 2 , ZHENG Ying 1   

  1. 1. Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2020-05-30 Online:2020-06-05
  • Contact: ZHENG Ying E-mail: zhengying@fudan.edu.cn

PDF

1207

摘要： 背景与目的：通过基于医院登记为基础的肺癌手术患者的随访资料，分析其1、3和5年观察生存率，为了解中国肺癌患者长期生存情况提供真实世界证据。方法：研究纳入2008年1月1日—2017年12月31日在复旦大学附属肿瘤医院接受手术的肺癌患者共7 753例，通过查阅患者复诊病史、电话随访和死因数据链接等方式收集患者的生存随访资料，随访统计时间截至2019年11月30日。采用Kaplan-Meier法估计患者1、3和5年总生存率（overall survival，OS），分性别根据年龄组、吸烟情况、诊断时间、肿瘤分期等特征分别描述。结果：男性肺癌手术患者经中位随访49.7个月后，5年OS为69.0%；女性患者经中位随访43.0个月后，5年OS为82.9%，显著优于男性。0、ⅠA、ⅠB、ⅡA、ⅡB、ⅢA和ⅢB期男性患者5年OS分别为100.0%、86.0%、74.6%、66.9%、55.2%、42.5%和41.8%，女性患者5年OS分别为100.0%、93.7%、78.5%、78.2%、62.9%、49.3%和33.0%。ⅠA、ⅠB、ⅢA期组女性患者OS优于男性。结论：本研究是目前国内最大规模的单中心肺癌患者的5年长期生存结果报告，经规范治疗后的肺癌患者的生存情况有显著改善，女性肺癌手术患者生存优于男性。肿瘤分期是影响肺癌患者生存的重要因素，应加强早诊早治，进一步提升患者生存率。

关键词: 肺癌, 生存报告, 医院登记

Abstract: Background and purpose: This study analyzed 1-, 3- and 5-year observed overall survival (OS) from a hospital-based cancer registry database, providing real world evidence of long-term survival among Chinese surgical lung cancer patients. Methods: A total of 7 753 lung cancer patients who underwent surgery in Fudan University Shanghai Cancer Center (FUSCC) from Jan. 1, 2008 to Dec. 31, 2017 were included in this analysis. Medical record review, telephone visits and death registry data linkage were carried out for collecting endpoint data. The last follow-up date was Nov. 30, 2019. Kaplan-Meier method was used to evaluate the 1-, 3- and 5-year OS rates, and results were described according to age group, smoking status, diagnosis time, tumor stage by gender. Results: The 5-year OS rate was 69.0% in male lung cancer patients who underwent surgery with a median follow-up time of 49.7 months and 82.9% in female patients with a median follow-up time of 43.0 months, which was significantly better for female patients. The 5-year OS rates were 100.0%, 86.0%, 74.6%, 66.9%, 55.2%, 42.5% and 41.8% in male patients and 100.0%, 93.7%, 78.5%, 78.2%, 62.9%, 49.3% and 33.0% in female patients with stage 0, ⅠA, ⅠB, ⅡA, ⅡB, ⅢA and ⅢB lung cancer, respectively. Female patients in stage ⅠA, ⅠB and ⅢA groups had better OS than male patients. Conclusion: This study is the 5-year long-term survival result report of the largest single-center lung cancer patients in China. The survival of lung cancer patients after standardized treatment is significantly improved. The survival of female lung cancer patients after surgery is better than that of male lung cancer patients. Tumor stage is an important factor affecting the survival of patients with lung cancer, and early diagnosis and treatment should be strengthened to further improve the survival of patients.

Key words: Lung cancer, Survival report, Hospital registration

沪公网安备 31010402003527号

沪ICP备12009617号

地址：上海市徐汇区东安路270号复旦大学附属肿瘤医院10号楼415室

邮编：200032 电话：021-64188274 E-mail：zgazzz@china-oncology.com

访问总数:; 今日访问总数:; 当前在线人数:

本系统由北京玛格泰克科技发展有限公司设计开发 技术支持：support@magtech.com.cn